

Genetic Testing for Prostate Cancer
Why Genetic Testing Matters for Prostate Cancer
Men with a first-degree relative diagnosed with prostate cancer have a 2-3x higher risk of developing the disease themselves.1 When the mutation is inherited, that risk compounds across generations. Genetic testing identifies the specific variants driving hereditary risk so you can take targeted action rather than waiting for symptoms
Comprehensive Gene Panel
Precision Over Guesswork
Protect Your Family
Guide Treatment Decisions
Genetic Counseling Included

Who Should Consider Hereditary Prostate Cancer Testing?
Family History of Prostate Cancer
Men with a father, brother, or son diagnosed with prostate cancer, especially at age 60 or younger, have a significantly elevated inherited risk that warrants genetic evaluation.5
Ashkenazi Jewish Ancestry
Individuals of Ashkenazi Jewish descent carry BRCA1 and BRCA2 mutations at a rate roughly ten times higher than the general population. These BRCA mutations also increase prostate cancer risk in men.6
Known BRCA Variant in the Family
If a close relative has already tested positive for a BRCA1, BRCA2, or other hereditary cancer mutation, male family members should strongly consider cascade testing to determine if they carry the same variant.7
Personal Prostate Cancer Diagnosis
Men diagnosed with prostate cancer, particularly high grade or metastatic disease, may benefit from genetic testing to explore treatment options and inform screening recommendations for family members.7
Multiple People On the Same Side of the Family with Similar Cancer Types
Families with relatives diagnosed with prostate, breast, ovarian, or pancreatic cancer across multiple generations on the same side of the family can carry a hereditary syndrome such as HBOC or Lynch Syndrome that affects all relatives.7
Proactive Risk Assessment
Even without a strong family history, many men elect genetic testing to be proactive about their health and understand their personal genetic risk of life-changing disease.
Key Genes Covered in Prostate Cancer Testing Panel
Our test analyzes the full spectrum of genes with clinically established links to hereditary prostate cancer risk.
Full gene list available here. Results reviewed by board-certified genetic counselors.
The most significant hereditary risk gene for prostate cancer; carriers face 5-8x higher average lifetime risk8
Moderately elevated prostate cancer risk; highly significant risk of developing breast and ovarian cancer in women7
A prostate specific susceptibility gene; the G84E variant significantly elevates early onset prostate cancer risk7
Linked to moderately elevated prostate cancer risk; particularly relevant for aggressive disease presentations7
Associated with Lynch Syndrome, which confers elevated risk of prostate cancer alongside colorectal and other cancers7
A Lynch Syndrome gene strongly linked to prostate cancer risk, especially in families with colorectal cancer history7
An emerging prostate cancer risk gene; interacts with BRCA2 and may influence disease aggressiveness7
Nibrin gene mutations are associated with elevated prostate cancer risk, particularly in men of Eastern European ancestry9
Simple, from Home to Results
Order Your Kit
Register online and receive a saliva collection kit shipped directly to your home within a few days.
Collect Your Sample
Provide a simple saliva sample at home, following the easy step-by-step instructions included in your kit.
Lab Analysis
Your sample is analyzed at a CLIA-accredited laboratory using advanced sequencing technology across the full gene panel.
Receive Results
Receive your results within 3 to 4 weeks. You can choose to schedule a complimentary consultation with a certified genetic counselor to review your findings.
Affordable Access for Everyone
Insurance Billing
Self-Pay Option
Knowledge Is Power. Get Tested Today.
References
- Staples MP, Giles GG, McCredie MR, Apicella C, Hopper JL. Risk of prostate cancer associated with a family history in an era of rapid increase in prostate cancer diagnosis (Australia). Cancer Causes Control. 2003;14(3):263-268. doi:10.1023/a:1023073203467
- American Cancer Society. Key statistics for prostate cancer. Cancer.org. Updated January 2026. Accessed June 2026. https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html
- Cleveland Clinic. Genetic mutations in humans. Cleveland Clinic. Reviewed February 2, 2022. Accessed June 2026. https://my.clevelandclinic.org/health/body/23095-genetic-mutations-in-humans
- Russo J, Giri VN. genetic testing and genetic counselling in prostate cancer. Nat Rev Urol. 2022;19(6):331-343. doi:10.1038/s41585-022-00580-7
- American Cancer Society. Prostate cancer risk factors. Cancer.org. Accessed June 2026. https://www.cancer.org/cancer/types/prostate-cancer/causes-risks-prevention/risk-factors.html
- Salami SS, Kaffenberger SD. genetic BRCA1/2 variants in Ashkenazi and non-Ashkenazi prostate cancer populations: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023;26(1):12-19. doi:10.1038/s41391-022-00585-6
- American Cancer Society. Genetic counseling and testing for prostate cancer risk. Cancer.org. Accessed June 2026. https://www.cancer.org/cancer/types/prostate-cancer/causes-risks-prevention/genetic-testing-and-counseling-for-prostate-cancer-risk.html
- Facing Our Risk of Cancer Empowered (FORCE). Cancer risk for people with a BRCA2 mutation. Facingourrisk.org. Accessed June 2026. https://www.facingourrisk.org/info/hereditary-cancer-and-genetic-testing/hereditary-cancer-genes-and-risk/genes-by-name/brca2/cancer-risk
- Zuhlke KA, Reams CMR, McHugh AMR, et al. Identification of a novel NBN truncating mutation in a family with hereditary prostate cancer. Breast Cancer Res Treat [published online ahead of print October 30, 2012]. doi:10.1007/s10549-012-2311-x